Abstract
Rationale: Teduglutide (TED) is a medical treatment for intestinal rehabilitation of patients with parenteral support (PS)-dependent short bowel syndrome (SBS) with chronic intestinal failure (cIF). Its clinical application is accompanied by a structured home care service program in Germany. Our retrolective study was designed to investigate treatment characteristics and outcome parameters in a clinical routine setting.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
